1 month retatrutide A summary slide of the TRIUMPH-1 data presented today by Dr. Ania Jastreboff at #ADA2026 🚨 TRIUMPH-1: Phase 3 Obesity Trial with Retatrutide 🚨 Retatrutide 💉, a once-weekly triple hormone receptor 1 Month Retatrutide Results: Clinical

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) slow gastric emptying, which may affect procedural safety during sedation

most companies offer monthly subscriptions to their products (a six-month supply of Lemmes pills, for example, costs $378)

On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]

For now, it serves as a reminder that healthcare is not one-size-fits-all, and even small adjustments may have significant impacts